Article Text

Download PDFPDF

Review
Review of Integrated Management of Childhood Illness (IMCI) in 16 countries in Central Asia and Europe: implications for primary healthcare in the era of universal health coverage
  1. Susanne Carai1,2,
  2. Aigul Kuttumuratova2,
  3. Larisa Boderscova3,
  4. Henrik Khachatryan4,
  5. Ivan Lejnev2,
  6. Kubanychbek Monolbaev5,
  7. Sami Uka6,
  8. Martin Weber2
  1. 1 University Witten Herdecke Faculty of Medicine, Witten, Germany
  2. 2 World Health Organization Regional Office for Europe, Copenhagen, Denmark
  3. 3 WHO CO Moldova, World Health Organization Regional Office for Europe, Chisinau, Moldova
  4. 4 WHO CO Armenia, World Health Organization Regional Office for Europe, Yerevan, Armenia
  5. 5 WHO CO Kyrgyzstan, World Health Organization Regional Office for Europe, Bishkek, Kyrgyzstan
  6. 6 WHO Office Pristina, World Health Organization Regional Office for Europe, Copenhagen, Denmark
  1. Correspondence to Susanne Carai, Medicine, Universitat Witten/Herdecke Department fur Humanmedizin, Witten 58448, Germany; sc{at}dischi.de

Abstract

The Integrated Management of Childhood Illness (IMCI) was introduced in Central Asia and Europe to address the absence of evidence-based guidelines, antibiotics misuse, polypharmacy and overhospitalisation. This study in 16 countries analyses status, strengths of and barriers to IMCI implementation and investigates how health systems affect the problems IMCI aims to address. 220 key informants were interviewed ranging from 5 to 37 per country (median 12). Data were analysed for arising themes and peer-reviewed. IMCI has not been fully used either as a strategy or as an algorithmic diagnostic and treatment decision tool. Inherent incentives include: economic factors taking precedence over evidence and the best interest of the child in treatment decisions; financing mechanisms and payment schemes incentivising unnecessary or prolonged hospitalisation; prescription of drugs other than IMCI drugs for revenue generation or because believed superior by doctors or parents; parents’ perception that the quality of care at the primary healthcare level is poor; preference for invasive treatment and medicalised care. Despite the long-standing recognition that supportive health systems are a requirement for IMCI implementation, efforts to address health system barriers have been limited. Making healthcare truly universal for children will require a shift towards health systems designed around and for children and away from systems centred on providers’ needs and parents’ expectations. Prerequisites will be sufficient remuneration, sound training, improved health literacy among parents, conducive laws and regulations and reimbursement systems with adequate checks and balances to ensure the best possible care.

  • paediatric practice
  • health service
  • general paediatrics
  • qualitative research
  • children's rights

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SC wrote the first draft of the manuscript and subsequent revision, and interpreted it in collaboration with the other authors. All authors contributed to the reviews in countries and the writing.

  • Funding This work was commissioned by the WHO Regional office for Europe and funded by the Bill and Melinda Gates Foundation.

  • Disclaimer The authors alone are responsible for the views expressed in this article, which do not necessarily represent the policies and positions of WHO.

  • Competing interests Most of the authors are or were WHO staff members and at some stage involved in the implementation of IMCI.

  • Patient consent for publication Not required.

  • Ethics approval This study was deemed exempt from ethical review by the WHO Ethics Review Committee (ERC.0002743003540/13).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.